Boehringer and Epizyme enter US$300m deal
According to BI, more than half of cancers can stem from functional errors in epigenetic modification, which diagnostically characterise the patient...
ProQR in licence deal with Ionis Pharmaceuticals
Currently, there is no approved therapy for the rare heritable defect in the rhodopsin (RHO) gene that causes blindness in-mid adulthood and affects...
Novo Nordisk reveals details about its R&D transformation
The job cuts will affect all R&D divisions. Then again, the company plans to establish a new business development unit in Cambridge (US) and...
Liquid biopsy: size matters
Usually, tumour DNA in blood is outnumbered by much larger quantities of noncancerous DNA. The novel method developed...
Calcium does not contribute to heart failure
In animal models, the group headed by Karl Toischer from University of Göttingen, showed that pharmacological decrease of calcium leak from...
Sugar replacement slows cancer growth
Feeding mannose either alone or alongside chemotherapy through a feeding tube three times a week and continuously via their drinking water was...
New cheap CRS-blockers at the horizon
In mice, the team headed by Bert Vogelstein and Shibin Zhou from Johns-Hopkins University in Baltimore demonstrated that severe...